Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Abstract: The invention relates to methods and reagents for analyzing samples for the presence of JC virus antibodies.

Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).

Abstract: Examples of techniques for generating streaming analytics applications are described herein. An example computer-implemented method includes receiving, via a processor, subject matter requirements in a semi-structured format. The method includes classifying, via the processor, the subject matter requirements based on a predefined taxonomy. The method includes extracting, via the processor, a list of entities from the subject matter requirements based on grammar. The method includes generating a solution based on a glossary and the list of extracted entities. The method includes generating, via the processor, a streaming analytics application based on the solution.

Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

Abstract: Techniques for informing a user about an agreement including agreement terms and trustworthiness of data source are described herein. In some examples, a processor receives agreement document data while the data is in route to a client device. A system receives network sources and content data of the agreement document. The network sources are to be processed by the processor with traffic analytics, and the content data is to be processed with text analytics. The output of these analytics is used to generate an agreement risk event for delivery to the client device with the original agreement document data.

Abstract: Techniques for informing a user about an agreement including agreement terms and trustworthiness of data source are described herein. In some examples, a processor receives agreement document data while the data is in route to a client device. A system receives network sources and content data of the agreement document. The network sources are to be processed by the processor with traffic analytics, and the content data is to be processed with text analytics. The output of these analytics is used to generate an agreement risk event for delivery to the client device with the original agreement document data.

Abstract: A computer-implemented method includes receiving data representing pre-existing instances of an analytics model developed over time; detecting changes in state of the analytics model over time to detect trends; generating a new instance of the analytics model that has been modified based on detected trends in the analytics model; generating new training data based on discovered trends of the analytics model over time; comparing a coverage of the new instance of the analytics model and coverages of the pre-existing instances of the analytics model with the new training data; and determining whether new instance of the analytics model have better coverage than the pre-existing instances of the analytics model with the new training data. A corresponding computer program product and system are also disclosed.

Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Abstract: Examples of techniques for detecting and preventing sensitive information leaks are described herein. In one example, a method for detection of sensitive information leaks comprises computing, via a processor, a set of rules that identify sensitive information, and sending, via the processor, the set of rules to a dispatcher application using a protocol. The method can also include detecting, via the processor, that at least one data block of the transmitted data matches the set of rules, and executing, via the processor, a corrective action in response to detecting that at least one of the transmitted data blocks matches the set of rules.

Abstract: Examples of techniques for detecting and preventing sensitive information leaks are described herein. In one example, a method for detection of sensitive information leaks includes computing, via a processor, a set of rules that identify sensitive information, and sending, via the processor, the set of rules to a dispatcher application using a protocol. The method can also include detecting, via the processor, that at least one data block of the transmitted data matches the set of rules, and executing, via the processor, a corrective action in response to detecting that at least one of the transmitted data blocks matches the set of rules.

Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.

Abstract: Examples of techniques for generating streaming analytics applications are described herein. An example computer-implemented method includes receiving, via a processor, subject matter requirements in a semi-structured format. The method includes classifying, via the processor, the subject matter requirements based on a predefined taxonomy. The method includes extracting, via the processor, a list of entities from the subject matter requirements based on grammar. The method includes generating a solution based on a glossary and the list of extracted entities. The method includes generating, via the processor, a streaming analytics application based on the solution.

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).

Abstract: Examples of techniques for generating streaming analytics applications are described herein. An example computer-implemented method includes receiving, via a processor, subject matter requirements in a semi-structured format. The method includes classifying, via the processor, the subject matter requirements based on a predefined taxonomy. The method includes extracting, via the processor, a list of entities from the subject matter requirements based on grammar. The method includes generating a solution based on a glossary and the list of extracted entities. The method includes generating, via the processor, a streaming analytics application based on the solution.